Relevant bibliographies by topics / Vaccine development

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Vaccine development'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccine development.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Vaccine development"

1

Alexander, NJ, and G. Bialy. "Contraceptive vaccine development." Reproduction, Fertility and Development 6, no. 3 (1994): 273. http://dx.doi.org/10.1071/rd9940273.

Full text
Abstract:
Recent advances in antigen definition and production have made the development of a contraceptive vaccine more attainable. Such a vaccine must evoke an immune response that blocks an indispensable step in the reproductive process. Vaccine research involves many approaches to fertility prevention. Vaccines are being developed that could interrupt fertility by inhibition of gonadotrophin release, the function of follicle-stimulating hormone or the effects of human chorionic gonadotrophin (hCG); alternatively, they may prevent fertilization by interfering with the transport of spermatozoa or with
APA, Harvard, Vancouver, ISO, and other styles
2

Mastroeni,, Pietro, and Nathalie Ménager. "Development of acquired immunity to Salmonella." Journal of Medical Microbiology 52, no. 6 (2003): 453–59. http://dx.doi.org/10.1099/jmm.0.05173-0.

Full text
Abstract:
Salmonella enterica serovar Typhi (S. typhi) causes human typhoid fever, a serious and widespread disease in developing countries. Other Salmonella serovars are associated with food-borne infections. The recent emergence of multi-drug-resistant Salmonella strains highlights the need for better preventive measures, including vaccination. The available vaccines against Salmonella infection do not confer optimal protection. The design of new Salmonella vaccines must be based on the identification of suitable virulence genes and on knowledge of the immunological mechanisms of resistance to the dis
APA, Harvard, Vancouver, ISO, and other styles
3

Xia, Yueting. "New Development of Vaccine Technology in Tumor Therapy." Theoretical and Natural Science 59, no. 1 (2024): 269–76. http://dx.doi.org/10.54254/2753-8818/59/20241442.

Full text
Abstract:
Abstract. Cancer vaccines are a crucial component of tumors immunotherapy, offering the advantage of minimizing adverse reactions to induce tumor regression. They also enable the establishment of lasting anti-tumor memory. Recent years have seen significant breakthroughs in cancer vaccines, including the customization of personalized vaccines and the transition from passive immunization to active treatment. Currently, most cancer vaccine future goals focus on improving cost and efficiency such as combining immunology and bioinformatics to predict more accurate vaccine epitopes. This paper focu
APA, Harvard, Vancouver, ISO, and other styles
4

Deng, Sheng-Qun, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang, and Hong-Juan Peng. "A Review on Dengue Vaccine Development." Vaccines 8, no. 1 (2020): 63. http://dx.doi.org/10.3390/vaccines8010063.

Full text
Abstract:
Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in
APA, Harvard, Vancouver, ISO, and other styles
5

Titanji, Vincent P. K. "New approaches to vaccines for endemic and pandemic diseases of Africa with particular focus on building local competencies in Cameroon." Journal of the Cameroon Academy of Sciences 17, no. 1 (2021): 75–83. http://dx.doi.org/10.4314/jcas.v17i1.6.

Full text
Abstract:
Vaccines have been recognized as major and effective tools for the control and eventual elimination of infectious diseases and cancer. This brief review examines vaccine classification and development pipeline as well as recent innovations driving the vaccine development process. Using COVID-19 as an example recent innovation in vaccine development are highlighted. The review ends with a call for intensified efforts to build vaccine production capacity in Cameroon and other other African countries.
 Les vaccins ont été reconnus comme des outils majeurs et efficaces pour le contrôle et l’é
APA, Harvard, Vancouver, ISO, and other styles
6

Aljohani, Salwa, Waleed M. Hussein, Istvan Toth, and Pavla Simerska. "Carbohydrates in Vaccine Development." Current Drug Delivery 16, no. 7 (2019): 609–17. http://dx.doi.org/10.2174/1567201816666190702153612.

Full text
Abstract:
Despite advances in the development of new vaccines, there are still some diseases with no vaccine solutions. Therefore, further efforts are required to more comprehensively discern the different antigenic components of these microorganisms on a molecular level. This review summarizes advancement in the development of new carbohydrate-based vaccines. Following traditional vaccine counterparts, the carbohydrate-based vaccines introduced a new approach in fighting infectious diseases. Carbohydrates have played various roles in the development of carbohydrate-based vaccines, which are described i
APA, Harvard, Vancouver, ISO, and other styles
7

AM, Aga. "Recent Advances in mRNA Vaccine Development." Open Access Journal of Microbiology & Biotechnology 8, no. 4 (2023): 1–17. http://dx.doi.org/10.23880/oajmb-16000275.

Full text
Abstract:
Messenger RNA vaccines are vaccine that utilizes a small segment of genetic material, messenger RNA (mRNA), to provide instructions to cells to produce a specific protein. This mRNA is synthesized in a laboratory and packaged into lipid nanoparticles, which protect and facilitate its entry into cells for protein synthesis. Upon injection into the muscle of the recipient, the mRNA instructs cells to produce a protein that is displayed on the surface of the cell, triggering an immune response. The immune system then produces antibodies and activates immune cells to target and eliminate the prote
APA, Harvard, Vancouver, ISO, and other styles
8

Suo, Zhaotaize. "Universal Vaccine Development Against COVID-19 and Influenza." E3S Web of Conferences 553 (2024): 05044. http://dx.doi.org/10.1051/e3sconf/202455305044.

Full text
Abstract:
Universal vaccines appeared as a favorable solution for the rapid mutation of viruses that cause pandemics. Sufficient immune protection, safe and efficient production methods, and low-cost funding are ideal properties for universal vaccines. Targeting conserved regions, use of adjuvants, cell-mediated immunity approaches, virus-like particles, and multimeric presentation of viral antigens are strategies to enhance vaccine Immunogenicity. Different types of vaccines have been put into clinical trials, such as messenger RNA vaccines, on-replicating viral vector vaccines, and recombinant protein
APA, Harvard, Vancouver, ISO, and other styles
9

Mboup, Elhadji Birane, Marie-Ève Hamelin, Julia Dubois, Manuel Rosa-Calatrava, and Guy Boivin. "Vaccine Development for Human Pneumoviruses." Vaccines 13, no. 6 (2025): 569. https://doi.org/10.3390/vaccines13060569.

Full text
Abstract:
Background: Pneumoviruses are etiologic agents of respiratory tract infections and a major cause of morbidity and mortality worldwide, particularly affecting young children, the elderly, and individuals with underlying clinical conditions. These viruses are associated with a significant burden, particularly in low- and middle-income countries, where reported deaths attributable to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in young children are important. Recent developments have been noted in the prevention of pneumoviral infections. Method: In this review, we analyzed
APA, Harvard, Vancouver, ISO, and other styles
10

Etefia, Etefia, and Paul Inyang Etoh. "Malaria Vaccine Development: Challenges and Prospects." Medical and Pharmaceutical Journal 2, no. 1 (2023): 28–42. http://dx.doi.org/10.55940/medphar202225.

Full text
Abstract:
Background: The development of a licensed malaria vaccine has been challenging due to the complex multi-stage life cycle, antigenic variation, and genetic diversity of Plasmodium. Numerous vaccines have been developed for various stages of Plasmodium, including pre-erythrocytic, blood stage, placenta, and transmission-blocking vaccines. However, none of these vaccines are completely effective and have high reactogenicity.Aim: The aim of this review is to examine the challenges and prospects in developing an effective malaria vaccine, with a focus on the development of a multi-stage or multival
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Vaccine development"

1

Da, Silva Pissarra Joana. "Development of a multi-epitope peptide vaccine against human leishmaniases." Thesis, Montpellier, 2019. http://www.theses.fr/2019MONTT013/document.

Full text
Abstract:
La leishmaniose est une maladie tropicale négligée à transmission vectorielle qui est endémique dans 98 pays dont les plus pauvres. Vingt espèces de Leishmania sont capables d’établir une infection intracellulaire au sein des macrophages humains, provoquant différentes manifestations cliniques. Le développement d'un vaccin contre les leishmanioses est étayé par des preuves d'immunité naturelle contre l'infection, induite par une réponse à médiation cellulaire de type Th1 dominante associée à la production d'IFN-γ, d'IL-2 et de TNF-α par des cellules T polyfonctionnelles TCD4+ et TCD8+, conduis
APA, Harvard, Vancouver, ISO, and other styles
2

Létourneau, Sven C. "HIV-1 vaccine development." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.442825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thompson, Fiona Mary. "Malaria immunology and vaccine development." Thesis, University of Southampton, 2008. https://eprints.soton.ac.uk/67626/.

Full text
Abstract:
This thesis describes work undertaken by the author at the University of Oxford. It begins by providing an introduction to malaria infection and pathophysiology, and a review of the latest attempts to produce an effective malaria vaccine. It goes on to describe the rationale behind the vaccines developed by the University of Oxford and others. A brief introduction to the process of planning and carrying out clinical trials of vaccines is then provided, and is followed by chapters describing two clinical trials, designed to test the safety, immunogenicity and then efficacy of candidate malaria
APA, Harvard, Vancouver, ISO, and other styles
4

Busch, Marc Gregory. "Evaluation of different SIV plasmid DNA vaccines : a model for HIV vaccine development /." For electronic version search Digital dissertations database. Restricted to UC campuses. Access is free to UC campus dissertations, 2004. http://uclibs.org/PID/11984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brune, Karl Dietrich. "Engineering modular platforms for rapid vaccine development." Thesis, University of Oxford, 2016. https://ora.ox.ac.uk/objects/uuid:41d57165-6e7c-4ca7-8025-b5ec31794c8c.

Full text
Abstract:
Vaccines have saved more lives than any other medical intervention. Recombinant vaccines provide unmatched safety profiles, but at the expense of reduced immunogenicity. Virus-like particles (VLPs) resemble viruses in size, shape and repetitive arrangement but are devoid of pathogenic genetic material and therefore safe. Poor immunogens can be rendered immunogenic by display on VLPs. Successfully decorating VLPs is still a major challenge. Genetic fusion or chemical modification is often time-consuming and can lead to misassembly or misfolding, which obstructs generation of the desired immune
APA, Harvard, Vancouver, ISO, and other styles
6

Flock, Margareta. "Development of a vaccine against strangles /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-500-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Poobalane, Saravanane. "Aeromonas hydrophila vaccine development using immunoproteomics." Thesis, University of Stirling, 2007. http://hdl.handle.net/1893/195.

Full text
Abstract:
Aeromonas hydrophila is an opportunistic pathogen that causes a wide range of symptoms and diseases in fish. Development of a commercial vaccine has been problematic due to the heterogenicity between isolates of A. hydrophila. A new approach using immunoproteomics was used in this study to try to develop a vaccine that would protect against a wide range of A. hydrophila strains. The virulence of 14 isolates of A. hydrophila from different geographical regions was determined in common carp (Cyprinus carpio) indicating that 6 isolates were virulent, while 8 isolates were avirulent. Expression of
APA, Harvard, Vancouver, ISO, and other styles
8

Beard, Jody. "Early development of a hookworm vaccine." Thesis, University of Nottingham, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.416306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aguilar, Roberto III. "Development of A Testicular Cancer Vaccine." Cleveland State University / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=csu1461270103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tarcha, Eric J. "Application of Immunoproteomics and Bioinformatics to coccidioidomycosis Vaccinology." University of Toledo Health Science Campus / OhioLINK, 2006. http://rave.ohiolink.edu/etdc/view?acc_num=mco1154441973.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Vaccine development"

1

Plotkin, Stanley A., ed. History of Vaccine Development. Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1339-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

E, Kaufmann S. H., ed. Concepts in vaccine development. Walter de Gruyter, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

service), SpringerLink (Online, ed. History of Vaccine Development. Springer Science+Business Media, LLC, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Koff, Wayne C., and Howard R. Six. Vaccine Research and Development. CRC Press, 2024. http://dx.doi.org/10.1201/9781003573838.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

L, Hoffman Stephen, ed. Malaria vaccine development: A multi-immune response approach. ASM Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lukashevich, Igor S., and Haval Shirwan, eds. Novel Technologies for Vaccine Development. Springer Vienna, 2014. http://dx.doi.org/10.1007/978-3-7091-1818-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Committee on Issues and Priorities for New Vaccine Development. New vaccine development: establishing priorities. National Academy P, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vanniasinkam, Thiru, Suresh K. Tikoo, and Siba K. Samal, eds. Viral Vectors in Veterinary Vaccine Development. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-51927-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bagnoli, Fabio, Giuseppe Del Giudice, Sanjay K. Phogat, and Rino Rappuoli, eds. Human Challenge Studies for Vaccine Development. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-63118-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rappuoli, Rino, and Fabio Bagnoli. Advanced vaccine research: Methods for the decade of vaccines. Caister Academic Press, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Vaccine development"

1

Karanikolas, Nicholas, and Jonathan Coleman. "Vaccine Development." In Bladder Cancer. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-417-9_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Blanchard, Thomas G., and Steven J. Czinn. "Vaccine Development." In Helicobacter pylori Infection and Immunity. Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0681-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Georgiev, Vassil St. "Vaccine Development." In National Institute of Allergy and Infectious Diseases, NIH. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-297-1_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Healer, Julie, and Alan F. Cowman. "Vaccine Development." In Molecular Parasitology. Springer Vienna, 2016. http://dx.doi.org/10.1007/978-3-7091-1416-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Poolman, J. "Vaccine development." In Neisseriae 1990, edited by Mark Achtman, Peter Kohl, Christian Marchal, Giovanna Morelli, Andrea Seiler, and Burghard Thiesen. De Gruyter, 1991. http://dx.doi.org/10.1515/9783110867787-032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Masci, Joseph R., and Elizabeth Bass. "Vaccine Development." In Ebola. CRC Press, 2017. http://dx.doi.org/10.1201/9781315119854-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

de Carvalho Clímaco, Marianna, Lucas Kraemer, and Ricardo Toshio Fujiwara. "Vaccine Development for Human Leishmaniasis." In Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_14.

Full text
Abstract:
AbstractThe development of vaccines for human leishmaniasis is one of the most important approaches for effectively controlling and/or eradicating the several forms of the disease. Based on the knowledge obtained from the practice of leishmanization and its protective immune response, several strategies have been used to develop vaccines against Leishmania species, such as the use of whole killed and attenuated parasites, recombinant proteins, and DNA vaccines. An ideal vaccine should be safe, effective, and immunogenic. Although several candidates have achieved safety and some level of effect
APA, Harvard, Vancouver, ISO, and other styles
8

Rajaram, Sankarasubramanian, Pirada Suphaphiphat, and Yingxia Wen. "Chapter 8. Cell Culture-based Influenza Vaccine Development." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Harris, Shannon L., and Peter C. Giardina. "Chapter 6. High-throughput Assays for Clinical Development." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Paschall, Amy V., and Fikri Y. Avci. "Chapter 5. Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs Against COVID-19." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00112.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccine development"

1

Malpani, Molika, and Umesh Telrandhe. "AI-powered Advancements in Drug Discovery and Vaccine Development to combat viral threats." In 2024 International Conference on Healthcare Innovations, Software and Engineering Technologies (HISET). IEEE, 2024. http://dx.doi.org/10.1109/hiset61796.2024.00097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vandu-Kwabe, Waseve, Maryam Aminu, and Helen I. Inabo. "Factors Affecting Immunity Level to Hepatitis B Vaccine in Some Parts of Nigeria." In 2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG). IEEE, 2024. http://dx.doi.org/10.1109/seb4sdg60871.2024.10629971.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hasanat, Raisa T., Nafees Mansoor, Nabeel Mohammed, Mohammad S. Rahman, Sifat Momen, and Mirza Rasheduzzaman. "Design and Development of an IoT Based Smart Vaccine Carrier and Real-Time Monitoring System." In 2024 6th International Conference on Sustainable Technologies for Industry 5.0 (STI). IEEE, 2024. https://doi.org/10.1109/sti64222.2024.10951133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eraghi, Vida. "Vaccine Development against Paratuberculosis." In Socratic Lectures 8. University of Lubljana Press, 2023. http://dx.doi.org/10.55295/psl.2023.i2.

Full text
Abstract:
Paratuberculosis or Johne’s disease (JD) is a chronic granulomatous enteritis affecting ruminants worldwide. It is caused by Mycobacterium avium subsp. paratuberculosis (MAP) and the rate of prevalence is increasing. Based on high economic impacts and public health concern, vaccine development against paratuberculosis is very essential. There is a lot of research articles about finding the best management approach for eradicating MAP, and also finding an ideal vaccine against the disease. But unfortunately, until now, there is no ideal management approach against the disease because we don’t h
APA, Harvard, Vancouver, ISO, and other styles
5

Krishnakumar, D., and K. S. Jaganathan. "Development of nasal HPV vaccine formulations." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.

Full text
Abstract:
Cervical cancer is the second most cancer in women worldwide with over 500000 new cases and 275000 deaths being registered every year. With nearly 73000 women dying every year, India now tops the world in cervical cancer deaths. India represents 26.4% of all women dying of cervical cancer globally. Cervical cancer estimated to be responsible for about 5% of human cancers worldwide. Currently available vaccines may not provide complete protection against all HPV types as the protection is primarily type specific. Furthermore, the available vaccines are delivered via intramuscular route and requ
APA, Harvard, Vancouver, ISO, and other styles
6

Kumar, Vishnu, Vijay Srinivasan, and Soundar Kumara. "Towards Smart Vaccine Manufacturing: A Preliminary Study During COVID-19." In ASME 2021 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/imece2021-70516.

Full text
Abstract:
Abstract Biopharmaceutical community is devising modern techniques to boost the development, production, and distribution of COVID-19 vaccines in large scale with tremendous speed. This has shifted the focus towards smart manufacturing of vaccines through vaccine platforms. Vaccine platforms have great potential to rapidly generate new vaccines and can overcome the challenges of the traditional vaccine manufacturing approach without compromising on safety and efficacy. This preliminary study compares the traditional and modern vaccine manufacturing techniques, reviews COVID-19 vaccine manufact
APA, Harvard, Vancouver, ISO, and other styles
7

Ermakova, M. Yu, S. V. Ivanov, A. A. Shishova, and A. A. Sinyugina. "OBTAINING MONOCLONAL ANTIBODIES TO POLIOVIRUS STRAINS SABIN FOR THE DEVELOPMENT OF AN ELISA TEST SYSTEM." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-182.

Full text
Abstract:
Poliomyelitis is an acute infectious disease caused by the poliovirus. Two types of vaccines are used to prevent poliomyelitis: oral (live) polio vaccine and inactivated polio vaccine [1]. To test the immunogenicity of vaccine preparations, there is a need to develop a highly specific ELISA test system that will allow for intratype differentiation of polioviruses.
APA, Harvard, Vancouver, ISO, and other styles
8

Asif Rasheed, Muhammad, Farrukh Jamil, and Kainaat Shoukat. "Vaccine Development for Newcastle Disease Virus in Poultry : Vaccine Development for NDV." In 2022 7th International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS). IEEE, 2022. http://dx.doi.org/10.1109/iciibms55689.2022.9971533.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhou, Luoyi Zhou, Ashenafi Kiros Wubshet, Jiangrong Zhang, et al. "The mRNA Vaccine Expressing Single and Fused Structural Proteins of Porcine Reproductive and Respiratory Syndrome Induces Strong Cellular and Humoral Immune Responses in BalB/C Mice." In БИОТЕХНОЛОГИЯ: НАУЧНЫЕ ИССЛЕДОВАНИЯ И СВЯЗЬ С ПРОИЗВОДСТВОМ. Всероссийский научно-исследовательский и технологический институт биологической промышленности, 2024. https://doi.org/10.47804/978-5-89904-038-2-2024-83-89.

Full text
Abstract:
Porcine reproductive and respiratory syndrome (PRRS) is a viral disease that causes significant economic losses. The development of a new and effective vaccine is key to the spread of the virus within the farm. Several vaccinations against PRRSV have been carried out using both traditional and alternative vaccines. Unfortunately, there is currently no vaccine that can completely stop this disease. Thus, our study aimed to develop an mRNA vaccine using antigens based on individual or fused PRRSV structural proteins. In this study, the nucleotide sequence of immunogenic mRNA was determined takin
APA, Harvard, Vancouver, ISO, and other styles
10

GIRARD, MARC P. "VACCINE DEVELOPMENT: A MAJOR CHALLENGE." In International Seminar on Nuclear War and Planetary Emergencies 34th Session. WORLD SCIENTIFIC, 2006. http://dx.doi.org/10.1142/9789812773890_0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccine development"

1

Bymark, Jeff. SARS-CoV-2 Vaccine Development. Iowa State University, 2021. http://dx.doi.org/10.31274/cc-20240624-1255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ivy, John M. Development of Dengue Vaccine, Phase 1. Defense Technical Information Center, 1987. http://dx.doi.org/10.21236/ada260281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Clements, John D., Lucy Freytag, Vijay John, and Tarun Mandal. Tulane/Xavier Vaccine Development/Engineering Project. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada614939.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Clements, John D., Lucy Freytag, Vijay John, and Tarun Mandal. Tulane/Xavier Vaccine Development/Engineering Project. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada482303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Konakanchi, Lakshmi sravya. Vaccine Development for Respiratory Syncytial Virus. Iowa State University, 2020. http://dx.doi.org/10.31274/cc-20240624-1577.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McKenzie, Ian. Vaccine Development Against Novel Breast Cancer Antigens. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada404639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lemon, Stanley M. New Approaches to Hepatitis A Vaccine Development. Defense Technical Information Center, 1992. http://dx.doi.org/10.21236/ada249594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lemon, Stanley M. New Approaches to Hepatitis A Vaccine Development. Defense Technical Information Center, 1994. http://dx.doi.org/10.21236/ada298648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reinhold, Vernon N. 'Coxiella Burnetii' Vaccine Development: Lipopolysaccharide Structural Analysis. Defense Technical Information Center, 1991. http://dx.doi.org/10.21236/ada233705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lemon, Stanley M. New Approaches to Hepatitis A Vaccine Development. Defense Technical Information Center, 1991. http://dx.doi.org/10.21236/ada237161.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Vaccine development' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography